结肠直肠肝转移的干预瘤学:从局部治疗到救援疗法
Dimitrios Xenos1, Vlasios S Sotirchos1, Platon M Dimopoulos2
1Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Biomedicines
|September 27, 2025
概括
干预瘤学为结直肠肝转移 (CLM) 提供先进的图像导向疗法. 治疗的范围从热除到动脉内疗法,扩大了外科手术之外的选择.
科学领域:
- 干预性瘤学干预性瘤学
- 放射学 放射学是一门学科.
- 肝胆道恶性瘤 肝胆道恶性瘤
背景情况:
- 结肠直肠肝转移 (CLM) 显著恶化患者的预后.
- 超过三分之一的结直肠癌患者患有肝转移.
- 干预瘤学已经为CLM提供了先进的局部区域疗法.
研究的目的:
- 审查CLM干预瘤治疗的演变.
- 检查各种地方区域治疗的指示.
- 提供当前治疗方式的全面概述.
主要方法:
- 审查历史和当前的干预瘤技术.
- 分析图像引导的局部区域疗法.
- 基于疾病程度的治疗指示的讨论.
主要成果:
- 从历史上看,肝切除是CLM的主要治疗选择.
- 热除是小的,可除的CLM的治愈选择.
- 非热性切除 (-90辐射分片切除,不可逆的电穿孔,组织) 和动脉内疗法 (Y90跨动脉放射栓塞,跨动脉化学栓塞) 为更广泛的疾病提供了替代方案.
结论:
- 干预瘤学为CLM提供了一系列以图像为导向的治疗方案.
- 治疗选择取决于CLM的大小,程度和患者因素.
- 这些疗法扩大了CLM患者的治疗和息选择.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K